 Expects to Report KEVEYIS dichlorphenamide Fourth Quarter 2020 Revenue of Approximately 8.2 Million and Full-Year 2020 Revenue of Approximately 30.7 Million, a 41.5 Percent Increase over 2019 Revenue of 21.7 Million 